1.
ChemMedChem
; 16(19): 3035-3043, 2021 10 06.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34237194
RESUMEN
The methylase METTL3 is the writer enzyme of the N6 -methyladenosine (m6 A) modification of RNA. Using a structure-based drug discovery approach, we identified a METTL3 inhibitor with potency in a biochemical assay of 280â nM, while its enantiomer is 100 times less active. We observed a dose-dependent reduction in the m6 A methylation level of mRNA in several cell lines treated with the inhibitor already after 16â h of treatment, which lasted for at least 6â days. Importantly, the prolonged incubation (up to 6â days) with the METTL3 inhibitor did not alter levels of other RNA modifications (i. e., m1 A, m6 Am , m7 G), suggesting selectivity of the developed compound towards other RNA methyltransferases.